Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Follicular 50Lymphoma, Non-Hodgkin 36Lymphoma, Large B-Cell, Diffuse 29Lymphoma 29Lymphoma, Mantle-Cell 26Lymphoma, B-Cell, Marginal Zone 22Lymphoma, B-Cell 18Recurrence 13Neoplasms 11Leukemia 7Leukemia, B-Cell 5Burkitt Lymphoma 5Leukemia, Hairy Cell 4Waldenstrom Macroglobulinemia 3Neoplasm, Residual 3Melanoma 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Disease 2Dendritic Cell Sarcoma, Interdigitating 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bronchiolitis Obliterans Syndrome 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Tumor Lysis Syndrome 1Solid Cancers 1

Interventions

Bevacizumab 7Paclitaxel 3vesencumab 2atezolizumab 2Immune Checkpoint Inhibitors 2Carboplatin 21-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one 2pertuzumab 1peginterferon alfa-2a 1parsatuzumab 1ovcon 35 1onartuzumab 1obinutuzumab 1ipatasertib 1emactuzumab 1Vitamin D 1Trastuzumab 1Rosiglitazone 1Pemetrexed 1Ipilimumab 1Interferon alpha-2 1HhAntag691 1Grape Seed Extract 1GDC-0623 1GDC-0152 1Docetaxel 1Cisplatin 1Capecitabine 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Cancers × obinutuzumab × Clear all
NCT02174172 2020-05-12

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
158 enrolled

Solid Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡